IL251385B - An inhaled formulation of rapamycin for the treatment of pulmonary hypertension - Google Patents
An inhaled formulation of rapamycin for the treatment of pulmonary hypertensionInfo
- Publication number
- IL251385B IL251385B IL251385A IL25138517A IL251385B IL 251385 B IL251385 B IL 251385B IL 251385 A IL251385 A IL 251385A IL 25138517 A IL25138517 A IL 25138517A IL 251385 B IL251385 B IL 251385B
- Authority
- IL
- Israel
- Prior art keywords
- inhalable
- treatment
- pulmonary hypertension
- rapamycin formulation
- rapamycin
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 208000002815 pulmonary hypertension Diseases 0.000 title 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
- 229960002930 sirolimus Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462060988P | 2014-10-07 | 2014-10-07 | |
| US201562144145P | 2015-04-07 | 2015-04-07 | |
| PCT/US2015/054550 WO2016057712A1 (en) | 2014-10-07 | 2015-10-07 | An inhalable rapamycin formulation for the treatment of pulmonary hypertension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL251385A0 IL251385A0 (en) | 2017-05-29 |
| IL251385B true IL251385B (en) | 2022-05-01 |
Family
ID=54360545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL251385A IL251385B (en) | 2014-10-07 | 2017-03-26 | An inhaled formulation of rapamycin for the treatment of pulmonary hypertension |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20170304276A1 (enExample) |
| EP (1) | EP3209330B1 (enExample) |
| JP (1) | JP6679584B2 (enExample) |
| KR (1) | KR20170095807A (enExample) |
| CN (1) | CN107249576A (enExample) |
| AU (1) | AU2015330905B2 (enExample) |
| BR (1) | BR112017006842A2 (enExample) |
| CA (1) | CA2963085C (enExample) |
| IL (1) | IL251385B (enExample) |
| MX (1) | MX389399B (enExample) |
| RU (1) | RU2732908C2 (enExample) |
| WO (1) | WO2016057712A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102256576B1 (ko) | 2013-10-08 | 2021-05-27 | 에이아이 테라퓨틱스, 인코포레이티드 | 림프관평활근종증의 치료를 위한 라파마이신 |
| RS64482B1 (sr) | 2014-04-04 | 2023-09-29 | Ai Therapeutics Inc | Inhalaciona formulacija rapamicina za lečenje stanja povezanih sa starenjem |
| AU2015330905B2 (en) | 2014-10-07 | 2021-02-25 | AI Therapeutics, Inc. | An inhalable rapamycin formulation for the treatment of pulmonary hypertension |
| WO2017192993A1 (en) * | 2016-05-05 | 2017-11-09 | Liquidia Technologies, Inc. | Dry powder treprostinil for the treatment of pulmonary hypertension |
| PT3505157T (pt) * | 2017-12-29 | 2022-02-18 | Celon Pharma Sa | Composição de cetamina em pó seco para administração pulmonar em depressão resistente ao tratamento |
| MX2020009740A (es) | 2018-03-20 | 2021-01-20 | Abraxis Bioscience Llc | Metodos para el tratamiento de trastornos del sistema nervioso central mediante la administracion de nanoparticulas de un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y una albumina. |
| JP7561628B2 (ja) * | 2018-05-22 | 2024-10-04 | アブラクシス バイオサイエンス， エルエルシー | 肺高血圧症を処置するための方法および組成物 |
| CN113795287A (zh) * | 2019-03-19 | 2021-12-14 | 阿布拉科斯生物科学有限公司 | 皮下施用包含mTOR抑制剂和白蛋白的纳米颗粒以治疗疾病 |
| MX2021013329A (es) | 2019-04-29 | 2022-03-17 | Insmed Inc | Composiciones de polvo seco de los profarmacos de treprostinil y métodos de uso de las mismas. |
| CN113444730A (zh) * | 2021-03-17 | 2021-09-28 | 昆明市延安医院 | 一种原发性肝细胞klotho基因转导干细胞筛选构建方法 |
| KR20250152464A (ko) * | 2024-04-16 | 2025-10-23 | 한미약품 주식회사 | 흡입제 조성물 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2517482A (en) | 1949-04-09 | 1950-08-01 | Sharp & Dohme Inc | Inhaler |
| GB1242211A (en) | 1967-08-08 | 1971-08-11 | Fisons Pharmaceuticals Ltd | Pharmaceutical composition |
| ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| DE3345722A1 (de) | 1983-12-17 | 1985-06-27 | Boehringer Ingelheim KG, 6507 Ingelheim | Inhalator |
| GB8909891D0 (en) * | 1989-04-28 | 1989-06-14 | Riker Laboratories Inc | Device |
| US5080899A (en) | 1991-02-22 | 1992-01-14 | American Home Products Corporation | Method of treating pulmonary inflammation |
| DE4140689B4 (de) | 1991-12-10 | 2007-11-22 | Boehringer Ingelheim Kg | Inhalationspulver und Verfahren zu ihrer Herstellung |
| AU688782B2 (en) | 1993-09-30 | 1998-03-19 | Wyeth | Rapamycin formulations for oral administration |
| NZ292980A (en) | 1994-09-29 | 1999-02-25 | Andaris Ltd | Smooth, spherical water-soluble microparticles as therapeutic or diagnostic vehicles |
| US5635161A (en) | 1995-06-07 | 1997-06-03 | Abbott Laboratories | Aerosol drug formulations containing vegetable oils |
| DE19523516C1 (de) * | 1995-06-30 | 1996-10-31 | Asta Medica Ag | Inhalator zum Verabreichen von Medikamenten aus Blisterpackungen |
| BE1009856A5 (fr) | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
| GB9606452D0 (en) | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
| AU735648B2 (en) | 1996-07-12 | 2001-07-12 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
| JP2001513078A (ja) | 1996-12-30 | 2001-08-28 | バテル・メモリアル・インスティテュート | 吸入により新生物を治療する製剤とその方法 |
| US6451784B1 (en) | 1996-12-30 | 2002-09-17 | Battellepharma, Inc. | Formulation and method for treating neoplasms by inhalation |
| US5989591A (en) | 1997-03-14 | 1999-11-23 | American Home Products Corporation | Rapamycin formulations for oral administration |
| US20040039047A1 (en) | 1998-08-11 | 2004-02-26 | Mark Zamoyski | Compositions and methods for treating lung cancers |
| DE60001623T2 (de) * | 1999-12-03 | 2003-12-18 | Pfizer Products Inc., Groton | Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel |
| US20040018228A1 (en) | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
| WO2003015521A1 (en) | 2001-08-20 | 2003-02-27 | Transave, Inc. | Treatment of cancers by inhalation of stable platinum-containing formulations |
| US20030059375A1 (en) | 2001-08-20 | 2003-03-27 | Transave, Inc. | Method for treating lung cancers |
| CA2486622A1 (en) | 2002-05-20 | 2003-12-04 | Research Development Foundation | Aerosol drug inhibition of lung metastases |
| US20050070567A1 (en) | 2002-08-12 | 2005-03-31 | The Regents Of The University Of Michigan | Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway |
| KR101369631B1 (ko) * | 2002-08-21 | 2014-03-05 | 노턴 헬스케어 리미티드 | 흡입용 조성물 |
| HUE040046T2 (hu) | 2002-12-09 | 2019-02-28 | Abraxis Bioscience Llc | Gyógyszerészeti készítmények és hatóanyagok beadására szolgáló eljárások |
| UA83484C2 (uk) | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
| AR043504A1 (es) | 2003-03-17 | 2005-08-03 | Novartis Ag | Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias |
| US20050119330A1 (en) | 2003-03-17 | 2005-06-02 | Kao Peter N. | Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases |
| AR050374A1 (es) | 2004-08-20 | 2006-10-18 | Wyeth Corp | Forma polimorfica de rafampicina |
| JP2008514706A (ja) | 2004-09-29 | 2008-05-08 | コーディス・コーポレイション | 安定非晶質ラパマイシン様化合物の薬学的投与形態 |
| GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| FR2882366B1 (fr) | 2005-02-18 | 2008-04-18 | Coletica Sa | Polymere reticule de carbohydrate, notamment a base de polysaccharides et/ou de polyols |
| RU2007130406A (ru) | 2005-03-02 | 2009-04-10 | Вайет (Us) | Очистка рапамицина |
| CA2599758A1 (en) * | 2005-03-08 | 2006-09-14 | Lifecycle Pharma A/S | Pharmaceutical compositions comprising sirolimus and/or an analogue thereof |
| JP2008533165A (ja) | 2005-03-17 | 2008-08-21 | エラン ファーマ インターナショナル リミティド | ナノ粒子免疫抑制性化合物の注射可能組成物 |
| CN1883474A (zh) | 2005-06-22 | 2006-12-27 | 华北制药集团新药研究开发有限责任公司 | 一种含大环内酯类化合物和多孔水不溶性亲水性载体的组合物 |
| US7446096B2 (en) | 2005-12-19 | 2008-11-04 | Industrial Technology Research Institute | Glutathione based delivery system |
| RU2008121713A (ru) | 2005-12-20 | 2010-01-27 | Вайет (Us) | Контроль стабильности лекарственной формы cci-779 посредством контроля примесей лекарственныхого вещества |
| GB0602123D0 (en) | 2006-02-02 | 2006-03-15 | Novartis Ag | Organic compounds |
| KR20080090493A (ko) | 2006-02-02 | 2008-10-08 | 노파르티스 아게 | 결절성 경화증의 치료 |
| US20100081681A1 (en) | 2006-08-16 | 2010-04-01 | Blagosklonny Mikhail V | Methods and compositions for preventing or treating age-related diseases |
| RU2009122202A (ru) | 2006-11-10 | 2010-12-20 | Биокон Лимитед (In) | Чистая форма рапамицина и способ ее выделения и очистки |
| US20080175887A1 (en) | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
| WO2008063576A2 (en) | 2006-11-20 | 2008-05-29 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| EP1938800A1 (en) | 2006-12-06 | 2008-07-02 | Ranbaxy Laboratories Limited | Sirolimus nanodispersion |
| EP1952807A1 (en) | 2007-01-24 | 2008-08-06 | LEK Pharmaceuticals D.D. | Sirolimus formulation |
| BRPI0807893A2 (pt) | 2007-02-20 | 2014-06-17 | Novartis Ag | Imidazoquinolinas como inibidores duais de lipídio quinase e mtor. |
| WO2008137148A2 (en) * | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Methods and compositions for treating pulmonary hypertension |
| EP2252275B1 (en) | 2008-02-13 | 2017-11-29 | Board of Regents, The University of Texas System | Templated open flocs of anisotropic particles for enhanced pulmonary delivery |
| ES2645692T3 (es) * | 2008-11-11 | 2017-12-07 | The Board Of Regents,The University Of Texas System | Microcápsulas de rapamicina y su uso para el tratamiento del cáncer |
| KR20110104120A (ko) | 2009-01-26 | 2011-09-21 | 테바 파마슈티컬 인더스트리즈 리미티드 | 극미립자를 이용한 담체 코팅 방법 |
| US20100196483A1 (en) | 2009-02-04 | 2010-08-05 | Activaero Gmbh Research & Development | Method for treatmentof severe and uncontrollable asthma |
| GB0905818D0 (en) | 2009-04-06 | 2009-05-20 | Airbus Uk Ltd | Coupling assembly |
| EP2965763B8 (en) | 2009-04-10 | 2018-08-15 | Haiyan Qi | Anti-aging agents |
| GB0908129D0 (en) * | 2009-05-12 | 2009-06-24 | Innovata Ltd | Composition |
| US9248110B2 (en) * | 2010-03-18 | 2016-02-02 | Steven Lehrer | Compositions and methods of treating and preventing lung cancer and lymphangioleiomyomatosis |
| PT105058B (pt) * | 2010-04-21 | 2013-04-17 | Hovione Farmaciencia S A | Processo para processamento de partículas de ingredientes activos farmacêuticos |
| WO2011163600A2 (en) | 2010-06-25 | 2011-12-29 | Apt Pharmaceuticals, Inc. | Tacrolimus compositions for aerosol administration |
| US20140037548A1 (en) * | 2010-06-28 | 2014-02-06 | The Board Of Trustees Of The Leland Standford Junior University | Treatment and prevention of diffuse parenchymal lung disease by selective active-site mTOR inhibitors |
| JP2013538830A (ja) | 2010-09-27 | 2013-10-17 | マイクロドース セラピューテクス，インコーポレイテッド | 吸入を用いる疾患治療のための方法及び組成物 |
| CN102670518B (zh) * | 2011-03-14 | 2014-08-20 | 齐鲁制药有限公司 | 一种难溶性药物球形颗粒的制备方法 |
| US20140067548A1 (en) | 2012-08-31 | 2014-03-06 | Sap Ag | Saving on device functionality for business calendar |
| JP2016522006A (ja) | 2013-03-28 | 2016-07-28 | エンドチョイス インコーポレイテッドＥｎｄｏｃｈｏｉｃｅ， Ｉｎｃ． | 小型マルチビュー素子内視鏡システム |
| KR102256576B1 (ko) * | 2013-10-08 | 2021-05-27 | 에이아이 테라퓨틱스, 인코포레이티드 | 림프관평활근종증의 치료를 위한 라파마이신 |
| US10307371B2 (en) | 2014-02-11 | 2019-06-04 | AI Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
| MX2016010373A (es) * | 2014-02-11 | 2016-11-30 | Lam Therapeutics Inc | Rapamicina para el tratamiento de linfangioleiomiomatosis. |
| RS64482B1 (sr) | 2014-04-04 | 2023-09-29 | Ai Therapeutics Inc | Inhalaciona formulacija rapamicina za lečenje stanja povezanih sa starenjem |
| DE102014005466A1 (de) | 2014-04-12 | 2015-10-15 | Klaus Düring | Verfahren zur Gewinnung von Napin und Cruciferin oder einem Gemisch davon aus Raps |
| AU2015330905B2 (en) | 2014-10-07 | 2021-02-25 | AI Therapeutics, Inc. | An inhalable rapamycin formulation for the treatment of pulmonary hypertension |
| MA40910A (fr) * | 2014-11-07 | 2017-09-12 | Civitas Therapeutics Inc | Poudres de rapamycine pour administration pulmonaire |
| WO2016130645A1 (en) | 2015-02-10 | 2016-08-18 | Lam Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
| CN108039392A (zh) | 2017-11-06 | 2018-05-15 | 北京汉能薄膜发电技术有限公司 | 铜铟镓硒化合物、油墨及其薄膜吸收层制备方法 |
-
2015
- 2015-10-07 AU AU2015330905A patent/AU2015330905B2/en active Active
- 2015-10-07 EP EP15787076.7A patent/EP3209330B1/en active Active
- 2015-10-07 JP JP2017518487A patent/JP6679584B2/ja active Active
- 2015-10-07 MX MX2017004440A patent/MX389399B/es unknown
- 2015-10-07 BR BR112017006842A patent/BR112017006842A2/pt not_active Application Discontinuation
- 2015-10-07 CN CN201580066403.9A patent/CN107249576A/zh active Pending
- 2015-10-07 US US15/516,219 patent/US20170304276A1/en not_active Abandoned
- 2015-10-07 KR KR1020177010965A patent/KR20170095807A/ko not_active Ceased
- 2015-10-07 RU RU2017115990A patent/RU2732908C2/ru active
- 2015-10-07 CA CA2963085A patent/CA2963085C/en active Active
- 2015-10-07 WO PCT/US2015/054550 patent/WO2016057712A1/en not_active Ceased
-
2017
- 2017-03-26 IL IL251385A patent/IL251385B/en unknown
-
2019
- 2019-12-27 US US16/728,615 patent/US11491143B2/en active Active
-
2022
- 2022-10-14 US US17/965,859 patent/US20230255944A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN107249576A (zh) | 2017-10-13 |
| AU2015330905B2 (en) | 2021-02-25 |
| JP6679584B2 (ja) | 2020-04-15 |
| US11491143B2 (en) | 2022-11-08 |
| IL251385A0 (en) | 2017-05-29 |
| US20170304276A1 (en) | 2017-10-26 |
| RU2732908C2 (ru) | 2020-09-24 |
| US20230255944A1 (en) | 2023-08-17 |
| BR112017006842A2 (pt) | 2017-12-12 |
| CA2963085C (en) | 2023-02-21 |
| KR20170095807A (ko) | 2017-08-23 |
| RU2017115990A3 (enExample) | 2019-05-08 |
| JP2017534604A (ja) | 2017-11-24 |
| CA2963085A1 (en) | 2016-04-14 |
| WO2016057712A1 (en) | 2016-04-14 |
| MX2017004440A (es) | 2017-11-01 |
| NZ731059A (en) | 2023-12-22 |
| US20200306230A1 (en) | 2020-10-01 |
| AU2015330905A1 (en) | 2017-05-18 |
| EP3209330A1 (en) | 2017-08-30 |
| EP3209330B1 (en) | 2022-02-23 |
| RU2017115990A (ru) | 2018-11-13 |
| MX389399B (es) | 2025-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279627A (en) | A method for treating depression | |
| IL248048A0 (en) | An inhalable formulation of rapamycin for the treatment of age-related symptoms | |
| IL251385B (en) | An inhaled formulation of rapamycin for the treatment of pulmonary hypertension | |
| IL247515A0 (en) | Snekribirock for the treatment of leprosy | |
| IL253945A0 (en) | kdm1a inhibitors to treat the disease | |
| IL247155A0 (en) | Rapamycin for the treatment of lymphangioleiomyomatosis | |
| EP3223712A4 (en) | Devices and methods for pulmonary hypertension treatment | |
| PT3169328T (pt) | Derivados de quinolina para o tratamento de doenças inflamatórias | |
| GB201500314D0 (en) | Pharmaceutical formulations for the treatment of pulmonary arterial hypertension | |
| GB201402070D0 (en) | Pharmaceutical compositions for the treatment of inflammatory disorders | |
| IL247599B (en) | Formulation that suppresses the immune system | |
| IL249502A0 (en) | Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of protein-associated diseases | |
| IL246721B (en) | History of 5-benzylisoquinoline for the treatment of cardiovascular diseases | |
| PT3122349T (pt) | Composições para o tratamento da autodigestão | |
| EP3137907A4 (en) | Methods and compositions for the diagnosis and treatment of kawasaki disease | |
| EP3215121C0 (en) | RAPAMYCIN POWDERS FOR PULMONARY ADMINISTRATION | |
| PT3113774T (pt) | Composições de grapiprant e métodos de utilização das mesmas | |
| SG11201609739UA (en) | Derivatives of dolaproine-dolaisoleuine peptides | |
| EP3145525A4 (en) | Use of microperoxidases for the treatment of carboxyhemoglobinemia | |
| GB201412010D0 (en) | Treatment of hypertransaminasemia | |
| PL3164110T3 (pl) | Kompozycje farmaceutyczne do leczenia łuszczycy | |
| HUP1400518A2 (hu) | Eljárás tofacitinib elõállítására | |
| IL251664A0 (en) | Inhalable formulation | |
| GB201408738D0 (en) | Components and methods for formulation of components | |
| HK1233709A1 (en) | Methods and compositions for the diagnosis and treatment of kawasaki disease |